(CRSP) Crispr Therapeutics - Ratings and Ratios
Gene-Edited Cell Therapy, CAR T Programs, In Vivo Editing, Diabetes Cell Therapy
Dividends
Currently no dividends paid| Risk via 10d forecast | |
|---|---|
| Volatility | 54.2% |
| Value at Risk 5%th | 79.8% |
| Relative Tail Risk | -10.45% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.37 |
| Alpha | -13.09 |
| CAGR/Max DD | -0.01 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.476 |
| Beta | 1.296 |
| Beta Downside | 0.958 |
| Drawdowns 3y | |
|---|---|
| Max DD | 64.91% |
| Mean DD | 31.16% |
| Median DD | 33.75% |
Description: CRSP Crispr Therapeutics November 06, 2025
CRISPR Therapeutics AG (NASDAQ:CRSP) is a Swiss-based biotechnology firm that leverages its proprietary CRISPR/Cas9 platform to develop gene-edited medicines for high-unmet-need diseases. Its core technology enables precise insertion, deletion or modification of DNA sequences, positioning the company at the forefront of the rapidly expanding gene-editing sector.
The company’s lead program, **CASGEVY**, is an ex-vivo edited hematopoietic stem-cell therapy designed to reactivate fetal hemoglobin and treat transfusion-dependent β-thalassemia, sickle-cell disease and related hemoglobinopathies. In addition, CRISPR Therapeutics is advancing a diversified pipeline that includes CAR-T candidates (CTX112 for CD19-positive cancers, CTX131 for CD70-expressing tumors), in-vivo editing programs targeting ANGPTL3 and Lp(a) for cardiovascular risk reduction (CTX310/CTX320), and an allogeneic, hypo-immune stem-cell product for type-1 diabetes (CTX211).
Strategic collaborations underpin the business model: a long-term partnership with Vertex Pharmaceuticals provides a $2.5 billion upfront and milestone structure, while alliances with Nkarta and Capsida expand the company’s CAR-T and delivery capabilities. As of the latest filing, CRISPR Therapeutics reported cash and cash equivalents of roughly **$1.3 billion**, giving it an estimated runway into 2025 under current burn rates, and a market-cap of about **$5 billion**, reflecting a price-to-sales multiple near 30×-high but consistent with the biotech sector’s premium on transformative gene-editing assets. The broader gene-therapy market is projected to grow at a **CAGR of ~20 %** through 2030, driven by advancing regulatory pathways and expanding payer acceptance.
For a deeper quantitative assessment of CRISPR Therapeutics’ valuation and risk profile, see the ValueRay analysis.
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income (-488.3m TTM) > 0 and > 6% of Revenue (6% = 2.26m TTM) |
| FCFTA -0.14 (>2.0%) and ΔFCFTA -5.03pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 4808 % (prev 919.6%; Δ 3889 pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.13 (>3.0%) and CFO -302.5m > Net Income -488.3m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 16.22 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (91.3m) change vs 12m ago 7.12% (target <= -2.0% for YES) |
| Gross Margin -355.6% (prev 30.60%; Δ -386.2pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 1.67% (prev 8.94%; Δ -7.26pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -8.62 (EBITDA TTM -529.5m / Interest Expense TTM -63.6m) >= 6 (WARN >= 3) |
Altman Z'' -4.75
| (A) 0.81 = (Total Current Assets 1.93b - Total Current Liabilities 119.0m) / Total Assets 2.25b |
| (B) -0.81 = Retained Earnings (Balance) -1.82b / Total Assets 2.25b |
| (C) -0.24 = EBIT TTM -548.2m / Avg Total Assets 2.25b |
| (D) -5.49 = Book Value of Equity -1.81b / Total Liabilities 329.3m |
| Total Rating: -4.75 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 31.29
| 1. Piotroski 0.0pt |
| 2. FCF Yield -9.84% |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.11 |
| 5. Debt/Ebitda 0.14 |
| 6. ROIC - WACC (= -40.54)% |
| 7. RoE -26.44% |
| 8. Rev. Trend -3.81% |
| 9. EPS Trend 30.40% |
What is the price of CRSP shares?
Over the past week, the price has changed by +4.33%, over one month by -16.44%, over three months by +1.54% and over the past year by -3.05%.
Is CRSP a buy, sell or hold?
- Strong Buy: 12
- Buy: 5
- Hold: 10
- Sell: 0
- Strong Sell: 1
What are the forecasts/targets for the CRSP price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 81.7 | 52.7% |
| Analysts Target Price | 81.7 | 52.7% |
| ValueRay Target Price | 53.1 | -0.7% |
CRSP Fundamental Data Overview November 25, 2025
P/E Forward = 23.3645
P/S = 124.8645
P/B = 2.4984
P/EG = -0.2142
Beta = 1.72
Revenue TTM = 37.6m USD
EBIT TTM = -548.2m USD
EBITDA TTM = -529.5m USD
Long Term Debt = 211.0m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 18.3m USD (from shortTermDebt, last quarter)
Debt = 211.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -75.5m USD (from netDebt column, last quarter)
Enterprise Value = 3.08b USD (4.79b + Debt 211.0m - CCE 1.92b)
Interest Coverage Ratio = -8.62 (Ebit TTM -548.2m / Interest Expense TTM -63.6m)
FCF Yield = -9.84% (FCF TTM -303.1m / Enterprise Value 3.08b)
FCF Margin = -805.2% (FCF TTM -303.1m / Revenue TTM 37.6m)
Net Margin = -1297 % (Net Income TTM -488.3m / Revenue TTM 37.6m)
Gross Margin = -355.6% ((Revenue TTM 37.6m - Cost of Revenue TTM 171.5m) / Revenue TTM)
Gross Margin QoQ = -7177 % (prev -4962 %)
Tobins Q-Ratio = 1.37 (Enterprise Value 3.08b / Total Assets 2.25b)
Interest Expense / Debt = 8.43% (Interest Expense 17.8m / Debt 211.0m)
Taxrate = -0.58% (negative due to tax credits) (619.0k / -105.8m)
NOPAT = -551.4m (EBIT -548.2m * (1 - -0.58%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 16.22 (Total Current Assets 1.93b / Total Current Liabilities 119.0m)
Debt / Equity = 0.11 (Debt 211.0m / totalStockholderEquity, last quarter 1.92b)
Debt / EBITDA = 0.14 (negative EBITDA) (Net Debt -75.5m / EBITDA -529.5m)
Debt / FCF = 0.25 (negative FCF - burning cash) (Net Debt -75.5m / FCF TTM -303.1m)
Total Stockholder Equity = 1.85b (last 4 quarters mean from totalStockholderEquity)
RoA = -21.75% (Net Income -488.3m / Total Assets 2.25b)
RoE = -26.44% (Net Income TTM -488.3m / Total Stockholder Equity 1.85b)
RoCE = -26.63% (EBIT -548.2m / Capital Employed (Equity 1.85b + L.T.Debt 211.0m))
RoIC = -29.85% (negative operating profit) (NOPAT -551.4m / Invested Capital 1.85b)
WACC = 10.69% (E(4.79b)/V(5.00b) * Re(10.79%) + D(211.0m)/V(5.00b) * Rd(8.43%) * (1-Tc(-0.01)))
Discount Rate = 10.79% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 5.96%
Fair Price DCF = unknown (Cash Flow -303.1m)
EPS Correlation: 30.40 | EPS CAGR: 19.59% | SUE: 0.29 | # QB: 0
Revenue Correlation: -3.81 | Revenue CAGR: -51.00% | SUE: -0.27 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-1.09 | Chg30d=+0.073 | Revisions Net=+1 | Analysts=6
EPS current Year (2025-12-31): EPS=-6.20 | Chg30d=+0.063 | Revisions Net=+4 | Growth EPS=-42.8% | Growth Revenue=-83.3%
EPS next Year (2026-12-31): EPS=-4.45 | Chg30d=+0.122 | Revisions Net=+6 | Growth EPS=+28.2% | Growth Revenue=+1909.8%
Additional Sources for CRSP Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle